BioPharma Dive May 7, 2024
The company has treated the first patient in an early trial of its cholesterol treatment Verve-102, a successor to its former lead candidate.
Dive Brief:
- Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene editing therapy for heart disease, about one month after a safety setback derailed what had been its lead candidate.
- The Phase 1b study, dubbed Heart-2, is testing Verve’s therapy in people with a hereditary form of high cholesterol known as HeFH for short, or who have premature coronary artery disease. The company is currently cleared to enroll patients in the U.K. and Canada, although it eventually plans to expand the study to the U.S.
- Verve’s therapy...
Today's Sponsors
Today's Sponsor